New shingles pain pill shows promise in major trial

NCT ID NCT07307976

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new oral medication called crisugabalin can provide better pain relief for people with shingles (herpes zoster) compared to standard treatments. The trial will enroll 750 adults with moderate to severe shingles pain. Participants will receive either crisugabalin plus usual care or usual care alone, and their pain levels will be tracked over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRISUGABALIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Beijing, Beijing 100070

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.